Biosimilars are ‘blockbuster drugs’ or the ‘affordable copies’ of expensive innovator products which are instrumental in reducing healthcare costs as well as improving patient access to important, lifesaving medications. They are biological products highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components.
